Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The index has shown a price loss of -15.60% this year. Over the last six months, there has been a stronger performance of -2.12%. The price of PACB leaped by -6.03% during the last 30 days period. For the last 5-days stocks have slided -5.40%.
Pacific Biosciences of California Inc (PACB) has a current stock price of $1.41. During the previous trading session, the stock witnessed a notable rise, reaching a high of $3.0 after opening at $1.41. The stock’s low for the day was $1.25, and it eventually closed at $1.42.
Pacific Biosciences of California Inc had a pretty Dodgy run when it comes to the market performance.
52-week price history of PACB Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Pacific Biosciences of California Inc’s current trading price is -48.18% away from its 52-week high, while its distance from the 52-week low is 65.61%. The stock’s price range over this timeframe has been between $0.85 and $2.72. The shares of the Healthcare sector company recorded a trading volume of approximately 1.72 million for the day, which was comparatively lower than the average daily volume of 9.26 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Pacific Biosciences of California Inc (PACB) has experienced a quarterly rise of 28.14% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 422.97M and boasts a workforce of 575 employees.
Expert Opinions: Analysts’ Ratings for Pacific Biosciences of California Inc
As of right now, 5 analysts are rating Pacific Biosciences of California Inc as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 7 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.2491, with a change in price of +0.1800. Similarly, Pacific Biosciences of California Inc recorded 8,663,690 in trading volume during the last 100 days, posting a change of +15.00%.
PACB’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for PACB stands at 7.63. Similarly, the long-term debt-to-equity ratio is also 7.60.
PACB Stock Stochastic Average
Pacific Biosciences of California Inc’s raw stochastic average for the past 50 days is currently at 58.24%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 19.15%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 22.70% and 17.63%, respectively.
